Tedizolid phosphate 200mg, once-daily, 6-day treatment has been demonstrated to be non-inferior to linezolid 600 mg, twice-daily, 10-day treatment in patients with ABSSSI, which was further investigated in a multicentre phase 3 study in a predominantly Asian population.